Thursday, Abraxis BioScience, Inc. (ABII), a biotechnology company, reported a wider loss for third quarter, hurt by higher expenses which more than offset the increase in revenue.
Abraxis' third quarter net loss widened to $37.7 million or $0.94 per share from $15.1 million or $0.38 per share in the same quarter last year.
For the current quarter, adjusted net loss for common shareholders was $24.2 million, or $0.60 per share, compared to a profit of $10.5 million or $0.26 per share in the prior year quarter. Total revenue for the quarter went up to $96.6 million from $93.4 million in the comparable quarter last year.
The Los Angeles, California-based company's total operating expense for the quarter was $117.90 million, up from $96.12 million in the prior year quarter mainly driven by the increase in research and development expenses.
Abraxis' reported research and development expenses of $51.03 million, compared to $21.0 million in the same quarter last year, primarily due to additional spending on Phase III clinical trials for non-small cell lung cancer, pancreatic cancer and melanoma and partially attributable to investments in early stage discovery and other research and development projects.
Gross Profit for the quarter declined to $76.91 million from $82.25 million and loss from operations increased to $40.99 million from $13.87 million in the year ago period.
For the nine months, net loss narrowed to $84.06 million or $2.10 per share from $94.89 million or $2.37 per share last year. Adjusted net loss was $39.94 million or $1.00 per share, compared to a profit of $28.66 million or $0.71 per share in the prior year. Year-to-date revenue went up to $254.33 million from $253.14 million last year.
ABII last tarded at $33.15, down $0.35 or 1.04% on a volume of 0.03 million shares and in after hours its trading up $0.29 or 0.87% at $33.43 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.